References:
1. Pui C-H, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013 Jul;50(3):185–96.
2. Pui C-H, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol [Internet]. 2015 Aug 24;33(27):2938–48. Available from: https://doi.org/10.1200/JCO.2014.59.1636
3. Gregoriou K, Craigie I, Gibson B, Mason A, Shaikh MG. Risk factors and management of corticosteroid-induced hyperglycaemia in paediatric acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2020;67(2):1–9.
4. Dare JM, Moppett JP, Shield JP, Hunt LP, Stevens MC. The impact of hyperglycemia on risk of infection and early death during induction therapy for acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2013 Dec;60(12).
5. Roberson JR, Spraker HL, Shelso J, Zhou Y, Inaba H, Metzger ML, et al. Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. Leukemia. 2009;23:245–50.
6. McCormick MC, Sharp E, Kalpatthi R, Zullo J, Gurtunca N, Zhang J, et al. Hyperglycemia requiring insulin during acute lymphoblastic leukemia induction chemotherapy is associated with increased adverse outcomes and healthcare costs. Pediatr Blood Cancer. 2020 Sep;67(9):e28475.
7. Grimes A, Mohamed A, Sopfe J, Hill R, Lynch J. Hyperglycemia During Childhood Cancer Therapy: Incidence, Implications, and Impact on Outcomes. J Natl Cancer Inst Monogr. 2019 Sep;2019(54):132–8.
8. Dacou-Voutetakis C, Palis J, Haidas S, Zannos-Mariolea L, Georgiopoulou P, Matsaniotis N. Abnormal glucose tolerance in children with acute leukemia. Effect of induction chemotherapy including L-asparaginase. Am J Pediatr Hematol Oncol. 1983;5(2):139–46.
9. Pastore G, Saracco P, Brach del Prever A, Iannacci L, Miniero R, Madon E. Glucose metabolism in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules. Acta Haematol. 1984;72(6):384–7.
10. Yetgin S, Yalçin SS, Ozbek N. Clinical value of glycated hemoglobin and fructosamine in the long-term glycemic control of children with acute lymphoblastic leukemia. Acta Paediatr Jpn Overseas Ed. 1998 Feb;40(1):52–6.
11. Shepherd EJ, Helliwell PA, Mace OJ, Morgan EL, Patel N, Kellett GL. Stress and glucocorticoid inhibit apical GLUT2-trafficking and intestinal glucose absorption in rat small intestine. J Physiol. 2004 Oct;560(Pt 1):281–90.
12. Beaudry JL, Riddell MC. Effects of glucocorticoids and exercise on pancreatic β-cell function and diabetes development. Diabetes Metab Res Rev. 2012 Oct;28(7):560–73.
13. Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med. 2011 Nov;78(11):748–56.
14. Brady V, Thosani S, Zhou S, Bassett R, Busaidy NL, Lavis V. Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy. Diabetes Technol Ther. 2014;16(12):874–9.
15. Dare JM, Moppett JP, Shield JP, Hunt LP, Stevens MC. The impact of hyperglycemia on risk of infection and early death during induction therapy for acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2013 Dec;60(12):E157-9.
16. Carpentieri U, Balch MT. Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors. J Pediatr. 1978 Nov;93(5):775–8.
17. Lowas SR, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009 Jul;52(7):814–8.
18. Howard SC, Pui C-H. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev [Internet]. 2002;16(4):225–43. Available from: https://www.sciencedirect.com/science/article/pii/S0268960X02000425
19. Spinola-Castro AM, Siviero-Miachon AA, Andreoni S, Tosta-Hernandez PDC, Macedo CRPD, Lee ML de M. Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited. Clin Adv Hematol Oncol. 2009 Jul;7(7):465–72.
20. Roberson JR, Spraker HL, Shelso J, Zhou Y, Inaba H, Metzger ML, et al. Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. Leukemia. 2009 Feb;23(2):245–50.
21. Pui CH, Burghen GA, Bowman WP, Aur RJA. Risk factors for hyperglycemia in children with leukemia receiving l-asparaginase and prednisone. J Pediatr. 1981;99(1):46–50.
22. Tsai MC, Huang HH, Chou YY, Cheng CN, Chen JS, Lin SJ. Risk Factors for Hyperglycemia during Chemotherapy for Acute Lymphoblastic Leukemia among Taiwanese Children. Pediatr Neonatol [Internet]. 2015;56(5):339–45. Available from: http://dx.doi.org/10.1016/j.pedneo.2015.01.008
23. Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2018;19(July):7–19.
24. Care D, Suppl SS. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(January):S15–33.
25. Tamez-Pérez HE. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes. 2015;6(8):1073.
26. Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes. 2014 Jan;6(1):9–20.
27. Saigí I, Pérez A. [Management of glucocorticoid induced hyperglycemia]. Rev Clin Esp. 2010 Sep;210(8):397–403.
28. Roberts A, James J, Dhatariya K, Agarwal N, Brake J, Brooks C, et al. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med. 2018;35(8):1011–7.
29. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16–38.
30. Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res Clin Pract [Internet]. 2013;99(3):277–80. Available from: http://dx.doi.org/10.1016/j.diabres.2012.12.023
31. Andria N, Moelyo AG, Riza M. During induction phase chemotherapy in childhood acute lymphoblastic leukemia. Paediatr Indones Indones. 2020;60(4):192–7.
32. Gonzalez-Gonzalez JG, Mireles-Zavala LG, Rodriguez-Gutierrez R, Gomez-Almaguer D, Lavalle-Gonzalez FJ, Tamez-Perez HE, et al. Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients. Diabetol Metab Syndr. 2013;5(1):1–7.
33. Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract. 2007;105(2):c54-7.
34. Ha Y, Lee K-H, Jung S, Lee S-W, Lee S-K, Park Y-B. Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. Lupus. 2011 Oct;20(10):1027–34.
35. Kim SY, Yoo C-G, Lee CT, Chung HS, Kim YW, Han SK, et al. Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J Korean Med Sci. 2011 Feb;26(2):264–7.
36. Stock W, Douer D, Deangelo DJ, Arellano M, Advani A, Damon L, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: Recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237–53.
37. Tools C. Asparaginase Dosing , Monitoring , and Toxicity Management – Adult / Pediatric – Inpatient / Ambulatory Clinical Practice Guideline. 2018;
38. Scott MG, Bruns DE, Boyd JC, Sacks DB. Tight glucose control in the intensive care unit: Are glucose meters up to the task? Clin Chem. 2009;55(1):18–20.
39. Dungan K, Chapman J, Braithwaite SS, Buse J. Glucose measurement: Confounding issues in setting targets for inpatient management. Diabetes Care. 2007;30(2):403–9.
40. Children TF. U nited K ingdom National Randomised Trial For Children and Young Adults with A cute L ymphoblastic L eukaemia and. 2012;
41. Wolfsdorf JI, Glaser N, Agus M, Fritsch M, Hanas R, Rewers A, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes. 2018;19(October):155–77.
42. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15(5):469–74.
43. Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol [Internet]. 2021;9(3):174–88. Available from: http://dx.doi.org/10.1016/S2213-8587(20)30381-8
44. Pichardo-Lowden AR, Fan CY, Gabbay RA. Management of hyperglycemia in the non-intensive care patient: featuring subcutaneous insulin protocols. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2011;17(2):249–60.
45. Abraham MB, Jones TW, Naranjo D, Karges B, Oduwole A, Tauschmann M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2018;19(October):178–92.
46. Finfer S, Chittock DR, Su SY-S, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar;360(13):1283–97.
47. Care D, Suppl SS. Diabetes care in the hospital: Standards of medical care in diabetes-2020. Diabetes Care. 2020;43(January):S193–202.
48. Danne T, Phillip M, Buckingham BA, Jarosz-Chobot P, Saboo B, Urakami T, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2018;19(March):115–35.
49. Pihoker C, Forsander G, Fantahun B, Virmani A, Corathers S, Benitez-Aguirre P, et al. ISPAD Clinical Practice Consensus Guidelines 2018: The delivery of ambulatory diabetes care to children and adolescents with diabetes. Pediatr Diabetes. 2018;19(May):84–104.
50. Phelan H, Lange K, Cengiz E, Gallego P, Majaliwa E, Pelicand J, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes education in children and adolescents. Pediatr Diabetes. 2018;19(August):75–83.
51. Bostrom B, Uppal P, Chu J, Messinger Y, Gandrud L, McEvoy R. Safety and efficacy of metformin for therapy-induced hyperglycemia in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2013;35(7):504–8.
52. Seelig E, Meyer S, Timper K, Nigro N, Bally M, Pernicova I, et al. Metformin prevents metabolic side effects during systemic glucocorticoid treatment. Eur J Endocrinol. 2017;176(3):349–58.
53. Wallace MD, Metzger NL. Optimizing the Treatment of Steroid-Induced Hyperglycemia. Vol. 52, Annals of Pharmacotherapy. SAGE Publications Inc.; 2018. p. 86–90.
54. Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol [Internet]. 2009/03/16. 2009 Jun;145(5):569–80. Available from: https://pubmed.ncbi.nlm.nih.gov/19344392
55. Ashour AE, Sayed-Ahmed MM, Abd-Allah AR, Korashy HM, Maayah ZH, Alkhalidi H, et al. Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats. Oxid Med Cell Longev. 2012;2012:434195.
56. Asensio-López MC, Sánchez-Más J, Pascual-Figal DA, Abenza S, Pérez-Martínez MT, Valdés M, et al. Involvement of ferritin heavy chain in the preventive effect of metformin against doxorubicin-induced cardiotoxicity. Free Radic Biol Med. 2013 Apr;57:188–200.
57. Van Raalte DH, Van Genugten RE, Linssen MML, Margriet D, Diamant M. Glucagon-Like Peptide-1 Receptor Agonist Treatment Prevents Glucocorticoid-Induced Glucose Intolerance and Islet-Cell Dysfunction in Humans. Diabetes Care. 2011;34:412–7.